23 October 2019 - Neurolixis' Parkinson's disease project showcased by French regional business accelerator

Neurolixis' development of NLX-112, a drug candidate for treatment of dyskinesia in Parkinson's disease and other movement disorders, was showcased by the Castres-Mazamet Technopole, a French regional entrepreneur accelerator in a video interview and article. In particular, these highlighted the recent financial support received by Neurolixis from the US Dept of Defense. The accelerator assists the French branch of Neurolixis in fundraising, recruitment and business networking.

See the full article here.


8 October 2019 - US Dept of Defense awards 861k$ grant to Neurolixis for movement disorder research

Neurolixis Inc. has been awarded a $861,000 grant by the US Department of Defense Congressionally Directed Medical Research Program to investigate the effects of NLX-112 as a potential treatment for Machado Joseph disease, a serious and rare genetic movement disorder. NLX-112 is an exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist which has already shown promising activity in models of Parkinson's disease. It is anticipated that NLX-112 could also be beneficial for treatment of other movement disorders, including Machado Joseph disease.

Read the full press release here.

United States Department of Defense Seal.svg